CL Colgate Palmolive (CL) Insider Trading, Ownership & Congress Trades
Consumer Goods · Perfumes, cosmetics & other toilet preparations · CIK 0000021665
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
929
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $23.6M priced
What the filings say about CL
Insiders, 180 days
-$32.0M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-09-02
Planned sales (Form 144), 90 days
$31.2M
5 notices
Colgate Palmolive insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COLGATE PALMOLIVE CO insiders sold a net $32.0M of stock across 109 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-29.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Feb 12, 2026.
- The trade is 15.4% of the 64,901 shares held after it.
- 2 other insiders sold within 30 days.
- 929 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO, CD, EMEA, APac, Skin Tsourapas Panagiotis sold about $920.5K of CL on Aug 24, 2026; 2 other insiders sold within 30 days and 929 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 3, 2023.
- The trade is 14.7% of the 28,373 shares held after it.
- 2 other insiders sold within 30 days.
- 929 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CAHILL JOHN T sold about $389.4K of CL on Aug 6, 2026; 2 other insiders sold within 30 days and 929 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Aug 4, 2026.
- The trade is 44.5% of the 362,231 shares held after it.
- 2 other insiders sold within 30 days.
- 929 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Wallace Noel R. sold about $14.9M of CL on Aug 5, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 929 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Feb 4, 2026.
- The trade is 44.5% of the 362,231 shares held after it.
- 2 other insiders sold within 30 days.
- 929 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Wallace Noel R. sold about $14.8M of CL on Aug 4, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 929 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 6, 2026.
- The trade is 16.9% of the 13,598 shares held after it.
- 1 other insider sold within 30 days.
- 929 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and Controller Malcolm Gregory sold about $203.4K of CL on May 15, 2026; 1 other insider sold within 30 days and 929 funds added in the latest 13F quarter.109 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$32.0M over 180 days
-$31.0M over 90 days
below 92% of Consumer Goods
Congress
no House purchase disclosed in the last 12 months
Funds
929 funds bought in last quarter
more than 98% of Consumer Goods
Revenue
+1.4% year over year
below 53% of Consumer Goods
Margin
10.5% net margin
more than 85% of Consumer Goods
Buybacks
$597.0M repurchased, FY to 2026-06-30
more than 93% of Consumer Goods
Short interest
2.3% of the float short (float per yahoo 2026-10-27) · 3.5 days to cover · settled 2026-10-15
below 53% of Consumer Goods
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CL: institutional holders (13F)
13F holdings, latest reported quarter
69,915,472 sh
$6.4B
52,246,333 sh
$4.8B
47,020,966 sh
$4.3B
24,021,137 sh
$2.2B
23,144,319 sh
$2.1B
Congress trades in CL
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-02 · disclosed 23 days later
$1,001 - $15,000
Sold 2026-08-31 · disclosed 25 days later
$1,001 - $15,000
Sold 2026-08-27 · disclosed 29 days later
$1,001 - $15,000
Sold 2026-08-19 · disclosed 13 days later
$1,001 - $15,000
Sold 2025-10-06 · disclosed 10 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Tsourapas Panagiotis
Filed 2026-08-24
$920.5K
CAHILL JOHN T
Filed 2026-08-06
$389.4K
Wallace Noel R.
Filed 2026-08-05
$14.9M
CAHILLANE STEVEN A
Filed 2026-08-04
$159.6K
Wallace Noel R.
Filed 2026-08-04
$14.8M
CL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$5.5M position · as of 2026-06-30
6.3%
DIAMOND HILL LARGE CAP FUND
$141.2M position · as of 2026-06-30
4.9%
State Street(R) Consumer Staples Select Sector SPDR(R) ETF
$641.1M position · as of 2026-06-30
4.7%
PROFUND VP CONSUMER STAPLES
$476.5K position · as of 2026-06-30
4.6%
Franklin Mutual Beacon Fund
$136.4M position · as of 2026-06-30
4.0%
DIAMOND HILL SELECT FUND
$20.5M position · as of 2026-06-30
3.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
73 registered trials, 14 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
0 active
49
Phase 3
7 active
10
Phase 4
7 active
8
Not applicable
0 active
1
Multi-phase
0 active
What changed recently
Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate
2026-10-21 · Completion moved 2026-07 → 2026-07-05
Phase 3
Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate
2026-10-21 · Active Not Recruiting → Completed
Phase 3
Clinical Study to Evaluate Remineralization Using an in Situ Model.
2026-10-21 · Not Yet Recruiting → Enrolling By Invitation
Phase 3
Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the
2026-09-25 · Not Yet Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Noel Wallace
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$16.5M
$12.3M
$6.4M
+4%
+12%
2024
$18.2M
$31.7M
$4.9M
+17%
+13%
2023
$17.1M
$19.5M
$4.7M
+0%
+8%
2022
$14.5M
$11.0M
$4.1M
-4%
+13%
2021
$15.5M
$18.0M
$4.1M
+2%
+14%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $32.0M sold by insiders over 180 days, 929 funds added last quarter, $31.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CL financials
Revenue growth
+1.4%
XBRL, annual
Net margin
10.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CL
| FY Dec 2025 | $20.4B |
| FY Dec 2024 | $20.1B |
| FY Dec 2023 | $19.5B |
| FY Dec 2022 | $18.0B |
| FY Dec 2021 | $17.4B |
| Jun 2026 | $5.4B |
| Mar 2026 | $5.3B |
| Dec 2025 | $5.2B |
| Sep 2025 | $5.1B |
| Jun 2025 | $5.1B |
| Mar 2025 | $4.9B |
| Dec 2024 | $4.9B |
| Sep 2024 | $5.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+9.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CL
| FY Dec 2025 | +10.5% |
| FY Dec 2024 | +14.4% |
| FY Dec 2023 | +11.8% |
| FY Dec 2022 | +9.9% |
| FY Dec 2021 | +12.4% |
| Jun 2026 | +12.9% |
| Mar 2026 | +12.1% |
| Dec 2025 | -0.7% |
| Sep 2025 | +14.3% |
| Jun 2025 | +14.5% |
| Mar 2025 | +14.1% |
| Dec 2024 | +14.9% |
| Sep 2024 | +14.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.9B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CL
| FY Dec 2025 | $3.6B |
| FY Dec 2024 | $3.5B |
| FY Dec 2023 | $3.0B |
| FY Dec 2022 | $1.9B |
| FY Dec 2021 | $2.8B |
| Jun 2026 | $867.0M |
| Mar 2026 | $609.0M |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.1B |
| Jun 2025 | $776.0M |
| Mar 2025 | $476.0M |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.0B |
At each fiscal year end
Single quarter
Debt to equity
37.87x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity CL
| FY Dec 2025 | 147.89x |
| FY Dec 2024 | 37.46x |
| FY Dec 2023 | 13.53x |
| FY Dec 2022 | 21.83x |
| FY Dec 2021 | 11.83x |
| Jun 2026 | 37.87x |
| Mar 2026 | 62.43x |
| Dec 2025 | 147.89x |
| Sep 2025 | 10.52x |
| Jun 2025 | 12.60x |
| Mar 2025 | 22.78x |
| Dec 2024 | 37.46x |
| Sep 2024 | 18.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.50x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt CL
| FY Dec 2025 | 0.53x |
| FY Dec 2024 | 0.52x |
| FY Dec 2023 | 0.45x |
| FY Dec 2022 | 0.29x |
| FY Dec 2021 | 0.46x |
| Jun 2026 | 0.50x |
| Mar 2026 | 0.48x |
| Dec 2025 | 0.53x |
| Sep 2025 | 0.45x |
| Jun 2025 | 0.44x |
| Mar 2025 | 0.49x |
| Dec 2024 | 0.52x |
| Sep 2024 | 0.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+434.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CL
| FY Dec 2025 | +1,602% |
| FY Dec 2024 | +704.0% |
| FY Dec 2023 | +455.4% |
| FY Dec 2022 | +353.5% |
| FY Dec 2021 | +320.4% |
| Jun 2026 | +434.3% |
| Mar 2026 | +821.7% |
| Dec 2025 | +1,602% |
| Sep 2025 | +450.3% |
| Jun 2025 | +705.2% |
| Mar 2025 | +977.1% |
| Dec 2024 | +704.0% |
| Sep 2024 | +1,347% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+11.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CL
| FY Dec 2025 | +13.2% |
| FY Dec 2024 | +17.8% |
| FY Dec 2023 | +14.3% |
| FY Dec 2022 | +11.6% |
| FY Dec 2021 | +14.0% |
| Jun 2026 | +11.9% |
| Mar 2026 | +12.6% |
| Dec 2025 | +13.2% |
| Sep 2025 | +17.0% |
| Jun 2025 | +17.1% |
| Mar 2025 | +17.4% |
| Dec 2024 | +17.8% |
| Sep 2024 | +17.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+28.3%
operating income after a 26.5% effective tax rate, over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CL
| FY Dec 2025 | +35.3% |
| FY Dec 2024 | +45.0% |
| FY Dec 2023 | +36.6% |
| FY Dec 2022 | +25.3% |
| FY Dec 2021 | +35.9% |
| Jun 2026 | +28.3% |
| Mar 2026 | +29.2% |
| Dec 2025 | +35.3% |
| Sep 2025 | +39.3% |
| Jun 2025 | +41.0% |
| Mar 2025 | +44.5% |
| Dec 2024 | +45.0% |
| Sep 2024 | +46.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+29.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CL
| FY Dec 2025 | +33.5% |
| FY Dec 2024 | +38.9% |
| FY Dec 2023 | +34.1% |
| FY Dec 2022 | +25.5% |
| FY Dec 2021 | +29.6% |
| Jun 2026 | +29.3% |
| Mar 2026 | +31.2% |
| Dec 2025 | +33.5% |
| Sep 2025 | +38.5% |
| Jun 2025 | +39.3% |
| Mar 2025 | +40.8% |
| Dec 2024 | +38.9% |
| Sep 2024 | +37.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
36.43x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CL
| FY Dec 2025 | 30.05x |
| FY Dec 2024 | 25.83x |
| FY Dec 2023 | 28.67x |
| FY Dec 2022 | 36.99x |
| FY Dec 2021 | 33.47x |
| Jun 2026 | 36.24x |
| Mar 2026 | 33.03x |
| Dec 2025 | 30.05x |
| Sep 2025 | 22.39x |
| Jun 2025 | 25.53x |
| Mar 2025 | 26.47x |
| Dec 2024 | 25.83x |
| Sep 2024 | 29.74x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$81.0B
market value at close 2026-10-27 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value CL
| FY Dec 2025 | $70.4B |
| FY Dec 2024 | $81.1B |
| FY Dec 2023 | $72.9B |
| FY Dec 2022 | $73.8B |
| FY Dec 2021 | $78.3B |
| Jun 2026 | $80.7B |
| Mar 2026 | $75.9B |
| Dec 2025 | $70.4B |
| Sep 2025 | $72.2B |
| Jun 2025 | $81.1B |
| Mar 2025 | $83.1B |
| Dec 2024 | $81.1B |
| Sep 2024 | $91.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield CL
| FY Dec 2025 | +5.7% |
| FY Dec 2024 | +4.8% |
| FY Dec 2023 | +4.6% |
| FY Dec 2022 | +2.8% |
| FY Dec 2021 | +3.8% |
| Jun 2026 | +5.3% |
| Mar 2026 | +5.5% |
| Dec 2025 | +5.7% |
| Sep 2025 | +5.3% |
| Jun 2025 | +4.6% |
| Mar 2025 | +4.6% |
| Dec 2024 | +4.8% |
| Sep 2024 | +4.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -29%, PEG needs growth
PEG, trailing CL
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.97x |
| FY Dec 2023 | 0.94x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 9.77x |
| Jun 2025 | 8.01x |
| Mar 2025 | 2.20x |
| Dec 2024 | 0.97x |
| Sep 2024 | 0.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $20.4B | $20.1B | $19.5B | $18.0B |
| Gross profit | $12.3B | $12.2B | $11.3B | $10.2B |
| Operating income | $3.3B | $4.3B | $4.0B | $2.9B |
| Net income | $2.1B | $2.9B | $2.3B | $1.8B |
| EPS (diluted) | 2.63 | 3.51 | 2.77 | 2.13 |
| Operating cash flow | $4.2B | $4.1B | $3.7B | $2.6B |
| Cash | $1.3B | $1.1B | $966.0M | $775.0M |
| Long-term debt | $6.9B | $7.3B | $8.2B | $8.7B |
| Buybacks | $1.2B | $1.7B | $1.1B | $1.3B |
SEC XBRL, fiscal years, as known on 2026-10-29
CL Stock Sonar score 6/7 axes
Find similar shapesCompareCL ranks highest on profitability (89th percentile) and institutional and government (49th), and lowest on insider conviction (4th), among Consumer Goods peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CL filings, in plain words
Are Colgate Palmolive insiders buying or selling CL?
In the 180 days to 2026-10-29, Colgate Palmolive insiders were net sellers, a net $32.0M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded CL?
Yes. In the year to 2026-10-29, 0 House members disclosed buying CL and 1 House member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-02.
Are there planned insider sales of CL?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-29, covering $31.2M of stock; the latest, by Tsourapas Panagiotis, was filed 2026-08-24.
Read the full summary
In the 180 days to 2026-10-29, Colgate Palmolive insiders were net sellers of CL, a net $32.0M across purchases and sales reported on Form 4 by 5 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-29, 0 members of Congress disclosed buying CL and 1 member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-02. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-29, covering $31.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
